Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 3/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405423 | 0.90 | PDE10A (0.42) | HRH3PDE10ADGAT1KCNH2HTR1A | |
| SCHEMBL2406177 | 0.86 | PDE10A (0.40) | HRH3PDE10ADGAT1ACACB | |
| SCHEMBL2406343 | 0.83 | PDE10A (0.41) | HRH3PDE10AHRH4HTR3ADGAT1 | |
| SCHEMBL2406349 | 0.83 | HRH3 (0.39) | HRH3PDE10AHRH4HTR3AHTR1A | |
| SCHEMBL2406077 | 0.83 | PDE10A (0.45) | HRH3PDE10AHRH4HTR3ADGAT1 | |
| SCHEMBL2406511 | 0.83 | PDE10A (0.43) | HRH3PDE10AHRH4HTR3ADGAT1 | |
| SCHEMBL2407749 | 0.82 | HRH3 (0.42) | HRH3PDE10AHRH4HTR3ADGAT1 | |
| SCHEMBL2408009 | 0.81 | HRH3 (0.42) | HRH3PDE10AHRH4HTR3ADGAT1 | |
| SCHEMBL1727924 | 0.81 | HRH3 (0.48) | HRH3PDE10AHRH4HTR3ADGAT1 | |
| SCHEMBL2406996 | 0.81 | HRH3 (0.41) | HRH3PDE10AHRH4HTR3ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | HRH3 42/4885PDE10A 2001/4885HRH4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.